News X4 cues up FDA verdict in April for WHIM syndrome drug The FDA has started a priority review of X4 Pharma’s mavorixafor, angling to become the first therapy for the rare disease WHIM syndrome, with a decision due by 30th April
News X4 Pharmaceuticals announces positive top-line results for W... X4 Pharmaceuticals has announced
News UK Biobank charts success of NHS imaging project The UK Biobank has completed the world's largest whole body imaging project, compiling more than a billion scans from 100,000 volunteers.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face